Abstract
Introduction
The short QT syndrome (SQTS) refers to a genetic condition of the heart in which the QT interval on the ECG is abnormally short, which leads to an increased risk of cardiac arrhythmias and sudden cardiac death (SCD) [1] . The first identified form of the SQTS (SQT1) was found to be caused by a missense mutation (N588K) to the human Ether-à-go-go-Related Gene (hERG), which rectifier potassium current, IKr [2] . The N588K-hERG channel mutation causes a gain-of-function to IKr through severely impaired inactivation over the physiological range of membrane potentials [3] . In a prior computational study from our group, this was shown to profoundly reduce ventricular effective refractory period (ERP), decreasing the minimal substrate size necessary to sustain re-entry and increasing the lifespan of re-entrant excitation waves [4] . Whereas multiple proarrhythmogenic effects of SQT1 in the human ventricles have been extensively characterised, less is known about the pharmacology of SQT1.
The current treatment for SQTS patients who show inducible ventricular tachycardia/fibrillation during programmed electrical stimulation is an implantable cardioverter-defibrillator (ICD) device [5] . However, such devices have a well-documented propensity to oversense T-waves (which often appear tall and peaked in SQTS patients) leading to erroneous identification of a tachyarrhythmic event, and are not particularly suitable for paediatric patients [6] , necessitating the investigation of alternative, pharmacological approaches.
An in vitro study by McPate et al. [7] used whole-cell patch clamp measurements of IKr/hERG in Chinese hamster ovary cells at 37ºC to evaluate the blocking potency of the class 1a anti-arrhythmic drug disopyramide (DISO), where it was seen that N588K mutant hERG channels caused only a modest 1.5-fold increase in the IC50 (half maximal inhibitory concentration), less than the 3.5-fold increase seen in quinidine, a commonly used drug in the SQT1 setting [8] . The efficacy of DISO in SQT1 in vitro suggests that the drug does not require block of the inactivated state in order to exert its inhibitory effect.
A pilot study showed that oral DISO restored both the QT interval and ventricular ERP in SQT1 patients in vivo, highlighting its potential use as an alternative to quinidine [9] . Here, an in silico approach was taken to gain mechanistic understanding into the action of DISO on human ventricular electrophysiology and consequent effects on QT interval prolongation.
2.

Methods
Model development
The O'Hara Rudy dynamic (ORd) model of the human ventricular action potential (AP) [10] was modified to include a previously-described Markov chain formulation of wild type (WT) and N588K mutant IKr/hERG, with kinetic changes accounting for impaired inactivation during the AP [11] . The gating scheme of the Markov chain model of the hERG channel is shown in Figure 1 . The SQT1 phenotype was described using a 1:1 ratio of WT to mutant hERG channels, as the N588K mutation is expressed heterozygously in vivo. The conductance of IKr was chosen based on the APD prolongation observed under experimental IKr block in the human ventricles [12] , and the conductances of IKs and IK1 adjusted accordingly. An IKr scaling factor ratio of 1.5:1 in epicardial (EPI) to endocardial (ENDO) cells, respectively, was applied as suggested in the study of Adeniran et al. [4] , in order to generate a tall, symmetrical T-wave in the pseudo-ECG of the SQT1 phenotype, as seen clinically [2] .
The steady-state effects of the class 1a drug DISO on IKr, INa, ICaL, and Ito were described using IC50 and nH (Hill coefficient) values taken from the literature [7] , [13] , [14] . The fractional block of each ionic current affected by DISO was modelled using simple pore block theory [15] , which postulates that the conductance gi of an ionic current type i is modified in a concentration-dependent manner such that 
Tissue simulations
Propagation of APs in tissue was described using the monodomain equation
where Vm is transmembrane potential, D is the diffusion coefficient tensor, Iion is the total ionic current, and Cm is the membrane capacitance. Eq (2) was discretised in space using the finite difference method and a spatial step of 0.15 mm. The 1D transmural model of human ventricle had a size of 15 mm, comprising 25 ENDO, 35 MCELL, and 40 EPI cells, with isotropic diffusion except for a 5-fold decrease in D at the MCELL:EPI border, as described in [4] . A stimulus was applied at the endocardial surface, eliciting a plane wave which propagated transmurally towards the epicardial surface. The pseudo-ECG was calculated using the method of Gima and Rudy [16] , i.e.
where is a unipolar potential generated by the 1D transmural fibre, a is the radius of the fibre, and r is the distance from a source point x to the field point x' recorded at a site located 2 cm away from the epicardial end of the strand. The QT interval was corrected according to Framingham's QT correction formula.
Results
Single cell investigations
At the single cell level, all concentrations of DISO simulated (5 μM, 10 μM, 20 μM) caused prolongation of the APD in SQT1 conditions at a basic cycle length (BCL) of 850 ms, which roughly corresponds to 70 bpm (Figure 3Ai ). The prolongation in APD was found to be predominantly due to the blocking actions of DISO on hERG channel IKr currents (Figure 3Aii) , with minimal changes in the APD resulting from block of other currents (not shown).
At a concentration of 10 μM, the fractional block due to DISO on affected ionic currents was as follows (in descending order): WT IKr/hERG (48.3%), N588K IKr/hERG (42.9%), INa (4.4%), Ito (3.0%), and ICaL (1.0%) Changes to the APD90 and peak IKr current density due to varying concentrations of DISO are summarised in Figure 3B , where it can be seen that both changed in a concentrationdependent manner. 
1D simulations
The 1D transmural ventricular strand model was also paced at a BCL of 850 ms, using the aforementioned protocol. Space-time plots of AP propagation in the 1D strand are shown in Figure 4 . The distribution of the membrane potential across the 1D transmural strand is shown using a standard rainbow palette, ranging from
The pseudo-ECG was computed in SQT1 conditions, and under application of 10 μM DISO. A concentration of 10 μM DISO prolonged the corrected QT interval from 263 ms to 338 ms.
Discussion
A biophysically-detailed Markov chain formulation of the SQT1 phenotype [11] has been incorporated into an established model of the human ventricular action potential incorporating transmural heterogeneities [10] . The resulting model has been used to investigate the functional consequences of the class 1a anti-arrhythmic agent disopyramide (DISO) on drug-induced APD and QT interval prolongation.
The therapeutic steady-state plasma levels of DISO are reported to be ~2.8-4.4 mg/L [17] , which corresponds to a dose of ~8.3-13.0 μM. Several doses (5 μM, 10 μM, 20 μM) were simulated in order to cover a range of possibilities, including low and high doses.
Our simulation results showed that combined blocking effects of DISO on IKr, INa, ICaL, and Ito caused significant prolongation of the action potential duration (APD). At a clinically-relevant concentration the IKr current was affected the most (even factoring in reduced blocking potency in SQT1-related N588K mutant hERG channels), with a smaller degree of INa/Ito block and almost negligible block of ICaL. In the 1D transmural ventricular strand model, a concentration of 10 μM produced a significant prolongation of the QT interval, bringing it much closer to the normal range of QT intervals. This is consistent with findings from the pilot study of Schimpf et al. [9] , in which oral DISO successfully prolonged the QT interval and ventricular ERP in vivo. Reduced ERP due to N588K mutant hERG channels in the human ventricles was shown to be an important factor in increasing susceptibility to re-entrant arrhythmias in a study by Adeniran et al. [4] . The APD prolongation due to application of DISO is likely to partially/fully restore the ERP, de-stabilising re-entrant circuits in tissue and increasing likelihood of arrhythmia termination.
Conclusion
As the SQTS is very rare, extensive clinical trials are currently not feasible. However, computational modelling can be a powerful tool in assessing drug-induced APD/QT interval prolongation, as well as helping to dissect underlying ionic mechanisms. In the present study, we have demonstrated that the class 1a antiarrhythmic agent disopyramide is an effective inhibitor of mutant hERG channels associated with SQT1 in the human ventricles. This study provides new insights into a potential pharmacological option in the treatment of SQT1 and other hERG-mediated forms of SQTS.
